Ignite Creation Date:
2025-12-24 @ 12:41 PM
Ignite Modification Date:
2025-12-28 @ 7:09 PM
Study NCT ID:
NCT00050661
Status:
COMPLETED
Last Update Posted:
2009-03-25
First Post:
2002-12-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011565', 'term': 'Psoriasis'}], 'ancestors': [{'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077561', 'term': 'Daclizumab'}], 'ancestors': [{'id': 'D061067', 'term': 'Antibodies, Monoclonal, Humanized'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 6}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '1997-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2009-03', 'completionDateStruct': {'date': '2008-04', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2009-03-24', 'studyFirstSubmitDate': '2002-12-17', 'studyFirstSubmitQcDate': '2002-12-17', 'lastUpdatePostDateStruct': {'date': '2009-03-25', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2002-12-18', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2004-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'time to disease relapse', 'timeFrame': 'After a course of NB-UVB treatment'}], 'secondaryOutcomes': [{'measure': 'Histologic assessment of disease activity at relapse for measures of epidermal hyperplasia, leukocyte infiltration, and expression of cytokine-induced inflammatory proteins.', 'timeFrame': 'before and after NB-UVB treatment'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['psoriasis', 'Cyclosporine', 'Daclizamub', 'anti-TAC', 'dermatology', 'skin', 'lesions'], 'conditions': ['Psoriasis']}, 'descriptionModule': {'briefSummary': 'This study is designed to study disease relapse after NBUVB and how the administration of Daclizumab/placebo alters disease relapse.', 'detailedDescription': 'The first part of the study involves NB-UVB light treatment, a well-established treatment to treat psoriasis. In the second part, we are testing a drug known as Humanized CD25 Monoclonal Antibody (anti-TAC) or placebo to prevent disease relapse. Anti-TAC is an injectable medicine that is also designed to treat psoriasis by blocking a part of the immune system that we believe contributes to the disease.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria\n\n1. Male or female patients with chronic psoriasis vulgaris (disease stable or worsening for \\> 6 months). Patients age 16 - 21 will be considered on a case to case basis.\n\n For those patients under the age of 18, parental consent will be obtained.\n2. Extensive skin involvement.\n3. Scale, thickness, and erythema in individual psoriasis lesions of at least moderate intensity.\n4. Psoriasis treated with emollients only for 2 weeks prior to treatment\n5. Patients with active psoriatic arthritis, if accompanied by psoriasis vulgaris involving more than 5% of the body surface.\n6. Patients that are appropriate for treatment with UVB.\n\nExclusion Criteria:\n\n1. Positive serology for HIV, Hepatitis B, or Hepatitis C.\n2. Positive β-HCG titer. For women of childbearing potential, unwillingness or inability to use a contraceptive device during this study if negative for β-HCG.\n3. Guttate psoriasis, pustular psoriasis, or whole body erythroderma.\n4. Active infection or persistent fever of unknown origin.\n5. Major concurrent illness, which could worsen following treatment with anti-TAC.'}, 'identificationModule': {'nctId': 'NCT00050661', 'briefTitle': 'To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris', 'organization': {'class': 'OTHER', 'fullName': 'Rockefeller University'}, 'officialTitle': 'Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody/ Placebo to Prevent Relapse of Psoriasis Vulgaris Following NBUVB Therapy', 'orgStudyIdInfo': {'id': 'JKR-0337'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Narrow Band Ultraviolet B', 'description': '312nm', 'interventionNames': ['Device: NB-UVB']}, {'type': 'EXPERIMENTAL', 'label': 'anti-TAC or placebo', 'interventionNames': ['Drug: Daclizumab']}], 'interventions': [{'name': 'Daclizumab', 'type': 'DRUG', 'otherNames': ['anti-TAC'], 'description': 'Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.', 'armGroupLabels': ['anti-TAC or placebo']}, {'name': 'NB-UVB', 'type': 'DEVICE', 'description': 'total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.', 'armGroupLabels': ['Narrow Band Ultraviolet B']}]}, 'contactsLocationsModule': {'locations': [{'zip': '10021', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Rockefeller University Hospital', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10021', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Rockefeller University', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Rockefeller University', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}], 'overallOfficials': [{'name': 'James Krueger, MD, PHD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Rockefeller University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rockefeller University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Facet Biotech', 'class': 'INDUSTRY'}], 'responsibleParty': {'oldNameTitle': 'James Krueger, MD, PhD', 'oldOrganization': 'Rockefeller University'}}}}